Not Logged In

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the development and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company also develops Oxycyte, a systemic perfluorocarbon product for use as oxygen carrier in the situations of acute ischemia; and a range of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. Its Oxycyte is under Phase II-b clinical trials for the treatment of traumatic brain injury. In addition, the company offers Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. It sells Dermacyte through distribution agreements, on-line retailers, and direct sales to physician and medical spa facilities. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.